“…KYNA, whose mammalian brain concentrations in adulthood are in the nanomolar to low micromolar range, exerts neuroactive properties as an antagonist of the alpha 7 nicotinic acetylcholine (α7nACh) receptors (Hilmas et al, 2001) and N-methyl-D-aspartate (NMDA) receptors (Perkins and Stone, 1982). KYNA also acts as a ligand of G protein-coupled receptor (GPR) 35 and the aryl hydrocarbon receptor (AhR), two signaling receptors that are functional in both the brain and peripheral organs (Divorty et al, 2015; Julliard et al, 2014; Mackenzie and Milligan, 2015; Moroni et al, 2012; Noakes, 2015). The second branch of the KP is predominantly metabolized in microglial cells (Guillemin et al, 2001, 2003; Heyes et al, 1996; Saito and Heyes, 1996), where the enzyme kynurenine 3-monooxygenase (KMO) metabolizes kynurenine to 3-hydroxykynurenine (3-HK), and the downstream catabolite 3-hydroxyanthranilic acid is formed by the enzyme kynureninase.…”